Proteomic analysis of gliomas

References

• Stummer W, Pichlmeier U, Meinel T, et al. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7(5)392–401
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason W P, van den Bent M J, and the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987–96
   PubMed Web of Science ®Google Scholar
• Louis D N, Holland E C, Cairncross G. Glioma classification—a molecular re-appraisal. Am J Pathol 2001; 159: 779–86
   PubMed Web of Science ®Google Scholar
• Bansal K, Liang M L, Rutka J T. Molecular biology of human gliomas. Technol Cancer Res Treat 2006; 5(3)185–94
   PubMedGoogle Scholar
• Kim J H, Robertson K D. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66: 7490–501
   PubMed Web of Science ®Google Scholar
• Hegi M E, Diserens A C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64: 2496–501
   PubMedGoogle Scholar
• Schwartz S A, Weil R J, Johnson M D, Toms S A, Caprioli R M. Protein profiling in brain tumours using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 2004; 10: 981–7
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Delaney M A, Noll E, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001; 7: 2387–95
   PubMedGoogle Scholar
• Fountoulakis M. Application of proteomics technologies in the investigation of the brain. Mass Spectrom Rev 2004; 23(4)231–58
   PubMedGoogle Scholar
• Lubec G, Krapfenbauer K, Fountoulakis M. Proteomics in brain research: potentials and limitations. Progr Neurobiol 2003; 69: 193–211
   PubMed Web of Science ®Google Scholar
• Banks R, Selby P. Clinical proteomics—insights into pathologies and benefits for patients. Lancet 2003; 362: 415–6
   PubMed Web of Science ®Google Scholar
• Mischak H, Apweiler R, Banks R E, et al. Clinical proteomics; a need to define the field and begin to set adequate standards. Proteomics Clin Appl 2007; 1: 148–56
   PubMed Web of Science ®Google Scholar
• Chuthapisith S, Layfield R, Kerr I D, Eremin O. Principles of proteomics and its applications in cancer. Surgeon 2007; 5: 14–22
   PubMedGoogle Scholar
• Stoeckli M, Chaurand P, Hallahan D E, Caprioli R M. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 2001; 7: 493–6
   PubMed Web of Science ®Google Scholar
• Caldwell R L, Caprioli R M. Tissue profiling by mass spectrometry: a review of methodology and applications. Mol Cell Proteomics 2005; 4: 394–401
   PubMed Web of Science ®Google Scholar
• Schwartz S A, Weil R J, Thompson R C, et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 2005; 65: 7674–81
   PubMed Web of Science ®Google Scholar
• Short D M, Heron I D, Birse-Archbold J L, et al. Apoptosis induced by staurosporine alters chaperone and endoplasmic reticulum (ER) proteins: Identification by quantitative proteomics. Proteomics 2007; 7(17)3085–3096
   PubMedGoogle Scholar
• Chumbalkar V C, Subhashini C, Dhople V M, et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005; 5: 1167–77
   PubMed Web of Science ®Google Scholar
• Furuta M, Weil R J, Vortmeyer A O, et al. Protein patterns and proteins that identify subtypes of glioblastoma. Oncogene 2004; 23: 6806–14
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Hiratsuka M, Inoue T, et al. Proteomics-based identification of differentially expressed genes in human gliomas. Biochem Biophysic Res Comm 2003; 309: 558–66
   PubMed Web of Science ®Google Scholar
• Hobbs S K, Shi G, Homer R, et al. Magnetic resonance Image-guided proetomics of human glioblastoma multiforme. J MRI 2003; 18: 530–6
   Google Scholar
• Khalil A A. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007; 98: 201–13
   PubMed Web of Science ®Google Scholar
• Odreman F, Vindigni M, Gonzales M L, et al. Proteomic studies on low- and high-Grade human brain astrocytomas. J Proteom Res 2005; 4: 698–708
   PubMed Web of Science ®Google Scholar
• Vogel T W, Zhuang Z, Li J, Okamoto H, et al. Proteins and protein pattern difference between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 2005; 11: 3624–32
   PubMed Web of Science ®Google Scholar
• Zhang R, Tremblat T-L, McDermid A, Thibault P, Stanimirovic D. Identification of differentially expressed proteins in human glioblastoma cell lines and tumours. Glia 2003; 42: 194–208
   PubMedGoogle Scholar
• Zhou L, Wang Y, Zhang Y-t, et al. Proteomics-based analysis of a pair of glioma cell lines with different tumour forming characteristics. Neurosci Lett 2006; 401: 59–64
   PubMedGoogle Scholar